Table 4.
Author and study | Year of inclusion | Country | Design | Total number patients | Patients | Age inclusion criteria | Median age | Number BC patients | Controls | Source of controls | Rate of contraceptive counseling | Contraceptive prevalence in women at risk of becoming pregnant unintentionally | Factors associated with contraceptive prevalence |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quinn et al., [13] Contraception |
2010 | USA | Written or online survey | 476 | Non gynecological cancer | <40 years old at diagnosis | 31,1 | 86 | 51 277 | General population estimation via the 2006–2010 National Survey for Family Growth | 66.7% |
Unintended pregnancy risk: 21% |
Lower use of tiers I-II: Increasing age: 1.07 per year; 95% CI [1.02–1.12]; p = 0.006 Previous BC history: OR 2.14; 95% CI [1.10–4.17]; p = 0.025 |
Maslow et al., [12] Contraception |
2011–2012 | USA | Online survey | 107 | Within 5 years of a cancer diagnosis | 18–45 years old at study inclusion | 56 | 65% | 57% |
Higher use of tiers I-II: Contraceptive counseling: OR 6.92; 95% CI [1.14–42.11]; p = 0.036 Non BC diagnosis: OR 3.60; 95% CI [1.03–12.64]; p = 0.046 |
|||
Dominick et al., [10] Obstetrics & Gynecology |
2011–2013 | USA | Annual online or telephone survey | 295 | Cancer survivors | 18–44 years old at study inclusion | 31,6 | 91 | 56% | 84% |
Higher use of tiers I-II: Family planning consult <1 year: RR 1.; 95% CI [1.1–1.5]; p < 0.01 Lower use of tiers I-II: ≥31 years old: RR 0.62; 95% CI [0.5–0.8]; p < 0.01 <2 years since cancer diagnosis:RR 0.66; 95% CI [0.5–0.9]; p < 0.01 BC diagnosis: RR 0.45; 95% CI [0.3–0.7]; p < 0.01 |
||
Hadnott et al., [24] Fertility and Sterility |
2015–2017 | USA | Online survey | 483 | Cancer survivors | 18–40 years old at study inclusion | 34 | 113 | 31% | 84% |
Lower use of contraception: Chemotherapy: PR 1.7; 95% CI [1.1–2.7] History of infertility: PR 2.; 95% CI [1.9–4.3] Infertility perception: PR 4.0, 95% CI [2.5–7.4] |
||
Mody et al., [21] J Cancer Surviv |
2014–2015 | USA | Online survey | 150 | History of Breast cancer within 5 years | 18–50 years old at study inclusion | 37,3 | 150 | 61% | 83% | NA | ||
Lambertini et al, [18] JAMA Network Open |
2012–2017 | France | Longitudinal evaluation | 2900 | Breast cancer survivors | 18–50 years old at study inclusion | 43,1 | 2900 | 45% at year 1 and 65.7% at year 2 during breast cancer follow-up |
38.9% at year 1 and 41.2% at year 2 during breast cancer follow-up |
Higher use of contraception Using contraception at diagnosis: aOR: 4.02; 95% CI [3.15–5.14], Being younger: aOR, 1.09; 95% CI, 1.07–1.13 per each decreasing year), having better sexual function aOR: 1.13; 95% CI [1.07–1.19], Having children: aOR: 4.21; 95% CI [1.8–9.86], Presence of leukorrhea: aOR: 1.32, 95% CI [1.03–1.7], Tamoxifen treatment alone: aOR: 1.39; 95% CI [1.01–1.92], Gynecologist follow-up at 1 year: aOR : 1.29; 95% CI [1.02–1.63], Partnered status: aOR: 1.61; 95% CI [1.07–2.44] |
||
Our study (2022) | 2018–2019 | France | Online survey | 517 | Breast cancer survivors | 18–43 years old at study inclusion | 37,1 | 517 | 1034 | Controls from the research network matched on age and parity | 66,30% | 78.9% |
Higher use of contraception: Younger age: OR 0.91; 95% CI [0.85–0.98]; p = 0.011 Information at BC diagnosis about chemo-induced ovarian damage: OR 2.47; 95% CI [1.39–4.37]; p = 0.002 Contraception information at BC diagnosis: OR 1.86; 95% CI [1.07–3.2]; p = 0.026 Anti-HER2 treatment: OR 2.46; 95% CI [1.39–6.16]; p = 0.018 |